The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.
The company received Chinese regulatory approval for a lung cancer assay last year and plans to seek approval for a liquid biopsy test this year.
Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
The American Society of Breast Surgeons updated consensus guidelines to recommend multigene panel testing for patients with cancer, including those who were tested many years ago.
While the study showed initial promise, further work will be necessary to clarify its performance for various clinical indications.
The company plans to use the funds to support development of an early cancer detection test and expansion of its CDx sales force.
The team plans to launch an RNA-seq diagnostic test out of the SickKids clinical laboratory in one year to complement clinical exome sequencing.
The company said RNA-seq will enable it to detect therapeutically relevant gene fusions better than DNA sequencing tests.
The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.
Natera plans to harness One Lambda's commercial infrastructure when it launches its cfDNA kidney transplant rejection test this year.